ArticleBioethics2026
Liminal Bioethics for Liminal Statuses: A New Method for Analysing Novel Biological Entities.
Article in Bioethics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Novel biological entities such as cell lines and organoids do not typically fit into established conceptual categories, such as 'human' or 'nonhuman', 'gift' or 'property'. This makes developing robust ethical principles or policy solutions difficult. In this article, we present a new approach to the ethics of novel biological entities, which we call 'liminal bioethics'. We argue that some entities are best understood as liminal; we should not try to shoehorn them into existing categories or modify our concepts to suit them. However, we must investigate which concepts help articulate an entity's liminal status most precisely. The choice of concepts, in turn, may suggest correspondingly liminal ethical principles or solutions for that entity. To demonstrate how this method works, we focus on immortalised cell lines as a test case, while also considering its implications for more recent breakthroughs in cell culture technology relating to organoids and assembloids. First, we demonstrate why the gift-property distinction is inadequate for framing the liminality of cell lines. We then argue for cell lines as being located in a liminal conceptual space between body part and organism, and discuss the conceptual shift that this entails for understanding the status of cell lines and organoids. We suggest that ethical principles in relation to cell lines should reflect this particular liminality; for example, commercial exchange of cell lines seems more acceptable than with body parts, but some means of respecting cell lines' continuing human connection should still be in place.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.